Roche AG is “losing money” in Russia, CEO Severin Schwan said in an interview published today, but remains committed to providing medicine to patients there.
“We can not just prevent cancer drugs from reaching Russian patients. There is an international consensus that drugs are exempt from sanctions,” Schwan told the Swiss newspaper TagesAnzeiger.
He added that prices are set in Russian rubles, which means that the pharmaceutical giant is losing money on Russian sales.
The announcement echoes the views of other drug giants, who have said they will supply Russia with the necessary drugs but are suspending other activities in response to the Russian invasion of Ukraine.
The CEO said that Roche has sales staff of 800 people in Russia.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
